13 completed. 12 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 12 |
| Phase 2 | 1 | Completed 1 |
Follow ACT-541468: new trials by email Literature Review of ACT-541468 trials Research Report on ACT-541468
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep Daridorexant, Placebo - Obstructive Sleep Apnea of Adult | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 20 | 2022-08-17 | 2023-04-04 |
| Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects ACT-541468 - Renal Insufficiency, Healthy | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 16 | 2019-09-24 | 2020-09-03 |
| A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects ACT-541468, Zopiclone 7.5 mg, Placebo - Healthy | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 56 | 2019-03-25 | 2019-10-31 |
| A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea ACT-541468, Placebo - Obstructive Sleep Apnea | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 28 | 2019-03-14 | 2019-12-19 |
| A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects ACT-541468 - Healthy | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 20 | 2019-03-09 | 2019-04-12 |
| A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease ACT-541468, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 28 | 2018-11-15 | 2019-09-23 |
| Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users ACT-541468, Suvorexant, Zolpidem - Healthy Recreational Drug Users | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 63 | 2018-09-07 | 2019-09-19 |
| A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects ACT-541468, ACT-541468 placebo, Ethanol 10% - Healthy | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 22 | 2018-08-28 | 2018-10-15 |
| A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin Rosuvastatin, ACT-541468 - Healthy Subjects | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 20 | 2017-10-30 | 2017-12-11 |
| A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects ACT-541468, placebo - Healthy Subjects | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 40 | 2017-03-15 | 2018-07-10 |
| A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam Midazolam, ACT-541468 - Healthy Subjects | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 20 | 2017-01-01 | 2018-07-10 |
| Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder ACT-541468, Placebo - Insomnia Disorder | Phase 2 | Completed | Idorsia Pharmaceuticals Ltd. | 58 | 2016-11-28 | 2020-04-24 |
| Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects ACT-541468, Diltiazem - Healthy Subjects | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 14 | 2015-09-01 | 2018-07-10 |
Pulmonary Disease, Chronic Obstructive (1) · Renal Insufficiency (1) · Sleep Apnea, Obstructive (1) · Sleep Initiation and Maintenance Disorders (1)
Idorsia Pharmaceuticals Ltd. (13)
Germany (7) · Netherlands (3) · Czechia (2) · United States (2) · Canada (1)
Marie-Laure Boof, PhD (2) · Clemens Muehlan (1) · Pascale Gasser (1)
PMID 32341187, PMID 33205362, PMID 33305817, PMID 34480579, PMID 35306405, PMID 42171662
2018 (2), 2016 (1), 2019 (1)